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ABSTRACT Recombinant human adenovirus serotype 5 (Ad5/35F-IL2) with modified fibres containing the 
C-terminal domain fiber-knob of human adenovirus serotype 35, carrying the gene of recombinant human 
IL-2, has been designed. As a result of the fiber modification, the adenovirus can efficiently deliver the genetic 
information to bone marrow leukocytes and the tumor blood cells KG-1A (human myeloblastic leukemia 
cells) and U937 (human histiocytic lymphoma cells), which are normally resistant to Ad5 infection. The flow 
cytometry data reveal that the modified Ad5/35F penetrates into a population of monocytes, granulocytes, 
and blast cells of human bone marrow. The expression of interleukin-2 in CAR-negative bone marrow 
leukocytes (3682.52 ± 134.21 pg/ml) and the cell lines KG-1A (748.3 ± 32.8 pg/ml) and U937 (421.5 ± 59.4 pg/
ml) transduced with adenovirus Ad5/35F-IL2 is demonstrated. The fiber-modified adenovirus can be used as a 
vector for the efficient gene delivery of interleukin-2 to human normal and tumor hematopoietic cells.
KEYWORDS adenovial vector; pseudotyping; interleukin-2; CD46; capsid modification.
ABBREVIATIONS Ad – human adenovirus; Ad5 – Ad serotype 5; Ad35 – Ad serotype 35; Ad5/35F – fiber-modified 
recombinant Ad5; UV – ultraviolet radiation; RBM – red bone marrow; IL2 – human interleukin-2; CAR – cox-
sackievirus and adenovirus receptor; aa – amino acid residue; pfu – plaque-forming unit.
INTRODUCTION
Among the vectors most commonly used to deliver 
genes to human and mammal cells are vectors based 
on the human adenovirus serotype 5 (Ad5). The ad-
vantages of these vectors are numerous; they are ca-
pable of transducing both dividing and non-dividing 
cells [1, 2]; the adenoviral DNA is not incorporated into 
the host cell genome and retains its extrachromosomal 
form; adenoviruses can be produced at a titer of over 
1010 pfu/ml, which  enables them to be used as living 
recombinant vaccines; and they ensure a high expres-
sion level of the target gene in a target cell. One of the 
drawbacks of  Ad5-based vectors is their low transduc-
ing activity with respect to  CAR-deficient and CAR-
negative cells. Among those, hematopoeitic cells occupy 
a significant place. This problem derives from the fact 
that  binding of the adenovirus capsid protein (fiber) 
and the membrane cell receptor CAR (coxsakievirus-
adenovirus receptor) is necessary for the primary inter-
action between Ad5 and a cell. Therefore, a deficiency 
or the total absence of these receptors on the cell sur-
face is a factor that limits  efficient gene delivery using 
Ad-5 based adenovectors.
This problem can be overcome via the genetic mod-
ification of the adenovirus’ fibers. The modification 
strategy consists in pseudotyping, i.e., the substitu-
tion of fibers or their individual domains for the fib-
ers or similar domains of the adenoviruses of other 
serotypes, which use receptors other than CAR recep-
tors for binding to the cell surface.  This approach was 
first used in 1996 by Gall et al; they constructed the 
Ad5 expressing Ad7 fiber and showed the change in 
vector tropism [3]. Krasnykh et al. [4] and Stevenson et 
al. [5] described the production of chimeric Ad5 vec-
tors containing the N-terminal and central domains 
of Ad5 fiber and the C-terminal domain of Ad3 fiber.     RESEARCH ARTICLES
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Substitution of Ad5 fiber for Ad35 fiber (Ad5/35F) 
was proposed for the efficient transduction of hemat-
opoietic cells [6]. The modification is made possible by 
the fact that Ad5 and Ad35 use different receptors 
in order to bind to the cell surface. It is CAR for Ad5 
and the CD46 molecule for Ad35 [7]; a high expression 
level of CD46 was detected on the surface of hemat-
opoietic cells. These chimeric adenoviruses can effi-
ciently transduce human hematopoietic [6] and den-
dritic cells [8].
 The described modification of the Ad5 fiber was 
used to construct a vector capable of efficiently pen-
etrating CAR-deficient hematopoietic cells, with the 
purpose of delivering the human interleukin-2 gene. 
The construction of this vector broadens the poten-
tial of using vectors based on human capsid-modified 
adenoviruses, in particular for genetic therapy in the 
treatment of leukemia of different etiologies.
EXPERIMENTAL
Plasmid vectors
The pZ35 plasmid containing the Ad5 genome with the 
Ad35 fiber knob domain and shuttle vector pShuttle-
CMV-IL2 containing the human interleukin-2 gene 
regulated by the human citomegalovirus promoter 
were previously constructed in the Gamaleya Re -
search Institute of Epidemiology and Microbiology [9]; 
pShuttle-CMV-EGFP was purchased from Stratagene 
(United States).
Viruses and bacterial strains
Recombinant Ad5 expressing a green fluorescent pro-
tein reporter gene (Ad5-EGFP), recombinant Ad5 ex-
pressing the human interleukin-2 gene (Ad5-IL2) ob-
tained earlier in the Gamaleya Research Institute of 
Epidemiology and Microbiology [9, 10], Eshcerichia coli 
strains DH5α and BJ5183.
Cell lines
In this study, the following transplantable human cell 
lines were used: HEK-293 (embryonic kidney cells 
transformed by the E1 region of the Ad5 genome), KG-
1A (myeloid leukemia cells), U937 (monocytic leukemia 
cells), and the primary leukocyte culture from red bone 
marrow (RBM) obtained from a healthy volunteer.
Obtainment of recombinant adenoviruses
Plasmid constructions carrying the full size adenovi-
rus genome with the modified fiber (Ad5/35F) and the 
target gene within the genome were obtained via ho-
mologous recombination in E. coli BJ5183. To this end, 
E. coli cells were co-transformed with a plasmid pair 
(pZ35 and pShuttle-CMV-EGFP) in order to obtain 
the plasmid with a full-size genome Ad5/35F and with 
green fluorescent protein gene (pAd5/35F-EGFP), 
and pZ35 and pShuttle-CMV-IL2 to obtain the plas-
mid with  full-size genome of Ad5/35F with the hu-
man interleukin-2 gene (pAd5/35F-IL2). Prior to the 
transformation, pZ35 and shuttle vectors (pShuttle-
CMV-EGFP and pShuttle-CMV-IL2) were linearized 
by PacI and PmeI, respectively. In the shuttle vectors, 
the target genes (EGFP and IL2) were regulated by 
the human cytomegalovirus promoter. Recombinant 
clones were analyzed using the polymerase chain re-
action (PCR) and restriction assay. Recombinant mod-
ified vectors Ad5/35F-EGFP and Ad5/35F-IL2 were 
obtained via the lipofection of plasmid constructions 
(pAd5/35F-EGFP and pAd5/35F-IL2) into the HEK-
293 line cells using Metafectene Pro agent (Biontex, 
Germany) according to the enclosed protocol. Recom-
binant adenoviruses were accumulated in HEK-293 
cells and detected on the basis of the development of 
the characteristic cytopathic effect. The presence of 
the target genes and fiber modification was proven 
by PCR and restriction assay. Recombinant modified 
adenoviruses were purified and concentrated by ce-
sium chloride density gradient ultracentrifugation 
of the lysates of infected cells. The concentration of 
adenovirus in the purified specimen was determined 
spectrophotometrically (λ = 260 nm) using the conver-
sion coefficient 1 OD = 1.12 × 1012 viral particles/ml. 
The titer of adenoviral specimens was determined by 
plaque formation assay on HEK-293 cells.
Determination of the physical stability 
of modified adenoviruses
The physical stability of modified adenoviruses was as-
sessed using the Ad5/35F-EGFP model by determin-
ing its thermal stability, according to the procedure 
described earlier [11].
Transduction of KG-1A and U937 human tumor 
blood cells with recombinant adenoviruses
KG-1A and U937 cells were seeded into 48-well plates 
at a concentration of 5 × 104 cells per well. The cells 
from the leukocytic fraction of human RBM obtained 
from a healthy donor were extracted by double centrif-
ugation in the density gradient of the Histopaque-1083 
commercial preparation (Sigma-Aldrich, Germany) ac-
cording to the enclosed protocol and seeded into 48-well 
plates at a concentration of 5 × 104 cells per well. On 
the following day, the cells were infected with the re-
combinant modified adenoviruses Ad5/35F-EGFP and 
Ad5/35F-IL2 and the control adenoviruses with fibers 
of the wild-type virus and analogous target genes Ad5-
EGFP and Ad5-IL2, at doses of 5 × 103, 104, and 5 × 104 
viral particles per cell.102 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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Analysis of the efficiency of penetration 
of adenoviruses into the cells and the 
expression level of the target gene
The efficiency of the penetration of the recombinant 
adenoviruses Ad5-EGFP and Ad/35F-EGFP into cells 
was assessed 48 h post infection via fluorescent micro-
scopy of the infected cells using the EGFP fluorescence 
intensity.
The expression level of the human IL2 gene in the 
cells infected with Ad5-IL2 and Ad5/35F-IL2 was as-
sessed 48 h post infection by determining the IL2 con-
centration in the culture medium of the infected cells 
by flow cytofluorimetry using the FlowCytomix Bend-
er Medsystems kit (Austria) according to the enclosed 
protocol. IL2 concentration in the specimens was calcu-
lated using the FlowCytomix Pro 2.2 software.
Determination of leukocyte populations 
of human RBM which are efficiently 
transduced by the modified adenovirus
The cells were infected with Ad5/35F-EGFP at a dose 
of 104 viral particles per cell, in order to determine the 
leukocyte populations of human RBM into which the 
modified adenovirus is capable of penetrating. Leuko-
cyte populations in RBM, namely monocytes, granulo-
cytes, T- and B-lymphocytes, and blast cells, were de-
termined 24 h post infection via flow cytofluorimetry, 
using fluorescently labelled antibodies against CD45 
(common leukocyte antigen). The virus-infected cells 
were detected by EGFP fluorescence and correlated 
with the corresponding leukocyte population.
RESULTS AND DISCUSSION
Obtaining  fiber-modified human 
recombinant adenoviruses serotype 5
The first strategy for obtaining the recombinant ad-
enovirus Ad5/35F described by Shayakhmetov et al. 
[6] consisted in the substitution of the central (shaft) 
and the C-terminal (knob) Ad5 fiber domains for the 
analogous domains of the Ad35 fiber. In order to con-
struct the modified virus, we used the new technology 
based on a single substitution of the C-terminal knob 
domain of the Ad5 fiber for the knob fibre domain [7]. 
The C-terminal knob and central shaft domains of 
the adenovirus fiber are linked by a short amino acid 
sequence, ensuring the relative mobility of the fiber 
knob domain. Most human adenoviruses contain a con-
servative threonine–leucine–tryptophan–threonine 
(TLWT) sequence in the mobile region between these 
domains [12]. The N-terminus of the knob domain of 
the Ad5 and Ad35 fibers also contains this sequence 
(Fig. 1).
Thus, in order to broaden the tropism of the virus 
relative to CD46-positive cells, and to achieve proper 
linking of the shaft and knob fibre domains, we substi-
tuted the knob domain of the Ad5 fiber (178 aa) for the 
knob domain of the Ad35 fiber (187 aa) after the TLWT 
sequence (Fig. 2).
Characterization of recombinant 
modified adenoviruses Ad5/35F
Recombinant modified adenoviruses Ad5/35-EGFP 
and Ad5/35F-IL2 were characterized according to the 
Fiber Ad5
Fiber Ad35
371  381  391  401  411
...KAMVPKLGTG  LSFDSTGAIT  VGNKNNDKL  TLWT  TPAPSPN  CRLNAEKDAK...
                                shaft domain                                                                      knob domain
                                shaft domain                                                                            knob domain
    101  111  121  131  141
...NGLETQNNKL  CAKLGNGLKF  NNGDICIKDS  IN  TLWT  GINP  PPNCQIVENT...
Fig. 1. Amino acid sequences of the C-terminal regions of fibers of human avenoviruses serotypes 5 and 35.
Concentration and titer of recombinant adenoviruses
Virus Concentration,  
viral particles/ml Titer, pfu/ml
Ad5-EGFP (4.82 ± 0.17) × 1012 (3.80 ± 0.83) × 1010
Ad5/35F-EGFP (2.54 ± 0.21) × 1012 (1.22 ± 0.34) × 1010
Ad5-IL2 (6.97 ± 0.19) × 1012 (5.85 ± 0.76) × 1010
Ad5/35F-IL2 (4.23 ± 0.17) × 1012 (2.12 ± 0.26) × 1010RESEARCH ARTICLES
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following parameters: the concentration of viral parti-
cles in a sample, titer of the adenoviral sample (Table), 
and the physical stability of adenoviruses upon heating 
(Fig. 3). Unmodified Ad5 samples containing expres-
sion cassettes with EGFP (Ad5-EGFP) and human IL2 
(Ad5-IL2) genes were used as a control. As can be seen 
from the Table, concentrations and titers of the sam-
ples of modified adenoviruses are comparable with the 
same parameters of the control samples of unmodified 
adenoviruses. Thus, the modification of the Ad5/35F 
adenovirus fiber had no considerable effect on its re-
production.
Since the modification of the adenovirus fibers in-
troduced by us could have some impact on the physical 
stability of adenoviruses, we assessed the stability of 
Ad5/35F-EGFP upon heating to +37 and +42oC during 
various time periods as compared with that of unmodi-
fied Ad5-EGFP. The thermal stability of Ad5/35F-
EGFP virions was shown to be comparable with that 
of the unmodified Ad5-EGFP adenovirus. Heating the 
adenovirus samples for 30 min at +37oC did not result 
in a significant decrease in their infectivity (Fig. 3A). 
The incubation of adenoviruses at +42oC led to the in-
activation of adenovirions in both samples: by 11–19% 
after heating for 15 min and by 23–45% after heating 
for 30 min (Fig. 3B).
The data on the thermal stability of the Ad5/35F-
EGFP adenovirus attest to the fact that this modifica-
Ad5 shaft
TLWT knob Ad5 
(178 aa)
Ad35 shaft
TLWT
knob Ad35 
(187 aa)
Ad5/35
Ad5 shaft
TLWTTLWT
knob Ad35 
(187 aa)
Ad5
Ad35
Fig. 2. Scheme for modification of fibers of human adenovirus serotype 5 by substitution of its C-terminal knob domain 
for the same domain of the fiber of human adenovirus serotype 35.
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Fig. 3. Thermal stability of fiber-modified adenovirions (Ad5/35F-EGFP) as compared with the unmodified adenovirions 
(Ad5-EGFP). A – Heating of adenovirus samples at +37oC for 5, 15, and 30 min. B – Heating of adenovirus samples at 
+42oC for 5, 15, and 30 min. Along the X axis, the heating conditions; along the Y axis, the relative efficiency of adeno-
virus penetration into HEK-293 cells assessed by EGFP fluorescence, %.104 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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tion of adenovirus fibers has no considerable effect on 
its physical stability.
Assessment of the efficiency of the delivery of 
genetic information by Ad5/35F-EGFP and 
Ad5/35F-IL2 adenoviruses to human hematopoietic 
tumor cells (KG-1A and U937 cell lines)
We selected KG-1A lines (myeloid leukemia cells) and 
U937 (monocytic leukemia cells) with a low level of ex-
pression of the primary adenoviral receptor CAR [13] 
and high level of CD46 expression [14], in order to as-
sess the efficiency of in vitro penetration of Ad5/35F-
EGFP and Ad5/35F-IL2 into human blood tumor cells, 
and to determine the expression level of the target 
genes in the virus-transduced cells. The multiplic-
ity of the infection was 5 × 103, 104, and 5 × 104 viral 
particles per cell. The efficiency of the penetration of 
Ad5/35F-EGFP into the cells was assessed according to 
the amount of cells expressing the reporter gene EGFP 
and fluorescing under UV irradiation (λ = 395 nm). It 
was demonstrated that as a result of fibre modification, 
the modified Ad5/35F-EGFP penetrated into U937 and 
KG-1A hematopoietic tumor cells more efficiently in 
comparison with the unmodified virus (Fig. 4). These 
results are consistent with the data obtained by other 
researchers who studied the efficiency of penetration 
of the modified Ad5/35F-EGFP virus into other lines 
of blood tumor cells [6] and into  primary lymphoid and 
myeloid leukemia cells [15].
The efficiency of expression of the human inter-
leukin-2 gene in the cell lines transduced with the re-
combinant modified Ad5/35-IL2 adenovirus turned out 
to be considerably higher than that in the cells trans-
duced with unmodified Ad5-IL2 (Fig. 5). The highest 
concentration of IL2 was noted in the cultural medium 
of the KG-1A cell line (748.3 ± 32.8 pg/ml) infected 
with Ad5/35F-IL2. U937 cells transduced with the 
modified adenovirus expressed the IL2 gene at a level 
of 421.5 ± 59.4 pg/ml. In the cells transduced with the 
unmodified Ad5-IL2 virus,  trace amounts of IL2 were 
expressed.
These results are consistent with the data on the 
level of CAR and CD46 molecules, the primary recep-
tors for Ad5 and Ad35 adhesion on the surface of the 
studied cell lines. Hematopoietic cells, including KG-
1A and U937 cells, are known to be CAR-negative [13]. 
Therefore, it is quite understandable that the unmodi-
fied Ad5 virtually did not penetrate into these cells;   
expression of the target genes in them was detected 
at a trace level. Meanwhile, due to a high level of CD46 
expression on the surface of KG-1A and U937 cells [14], 
the modified Ad5/35F had an enhanced ability to pen-
etrate into these cells, which ensured a high expression 
level of the target genes in them.
Assessment of the efficiency in delivering the 
genetic information to  normal leukocytes 
of human red bone marrow (RBM) by 
recombinant modified adenoviruses
The modified Ad5/35F adenovirus efficiently transduc-
es CAR-negative tumor blood cells and ensures the ex-
pression of the target genes introduced into its genome 
in these cells. It was therefore decided to determine the 
efficiency in delivering the genetic information via ad-
Ad5-EGFP   Ad5/35F-EGFP
KG-1A 
U937 
Fig. 4. Penetration efficiency of the modified Ad5/35-
EGFP virus into KG-1A and U937 lines of human tumor 
blood cells 48 h after infection.
800
700
600
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400
300
200
100
0
KG-1A   U937
k- 
Ad5-IL2 
Ad5/35F-IL2
Fig. 5. Expression level of the human interleukin-2 gene in 
KG-1A and U937 lines of human tumor blood cells trans-
duced with recombinant adenoviruses 48 h after infection. 
Along the X axis, interleukin-2 concentration in the culture 
medium of infected cells, pg/ml.RESEARCH ARTICLES
 VOL. 3  № 3 (10)  2011  | ACTA NATURAE | 105
enovectors (Ad5/35F-EGFP and Ad5/35F-IL2) to the 
cells of the leukocytic fraction of RBM obtained from a 
healthy blood donor. The reason for this interest is the 
potential of using the modified adenovirus as a vector 
for the efficient selective ex vivo delivery of genetic in-
formation to hematopoietic and immunocompetent hu-
man cells. The leukocytes extracted from a RBM sam-
ple taken from a healthy blood donor were transfected 
with modified (Ad5/35F-EGFP and Ad5/35-IL2) and 
unmodified (Ad5-EGFP and Ad5-IL2) adenovectors 
at different doses. As a result, the modified Ad5/35F-
EGFP vector was shown to penetrate into RBM leuko-
cytes more efficiently in comparison with Ad5-EGFP, 
which was indicated by the intense fluorescence of 80% 
of all cells resulting from the EGFP expression (Fig. 6). 
IL2 concentration upon cell transduction with vectors 
with the target IL2 gene in the culture medium of cells 
infected with the modified Ad5/35-IL2 was equal to 
3682.52 ± 134.21 pg/ml; approximately 30-fold higher 
than the IL2 concentration in the leukocyte culture 
medium transduced with the unmodified Ad5-IL2 
(Fig. 7).
Taking into account the fact that the cells of the leu-
kocyte fraction of the RBM contain a number of het-
erogeneous cell populations, we decided to determine 
the populations of leukocytes into which the modified 
adenovirus efficiently penetrates.
RBM leukocytes were infected with the modified 
Ad5/35F-EGFP at a dose of 5 × 104 viral particles per 
cell. The populations of cells efficiently transduced by 
the modified adenovirus were revealed 24 h after in-
fection by flow cytofluorimetry using fluorescently 
labelled antibodies against the common leukocyte anti-
gen CD45 according to the cell size, the expression level 
of CD45 antigen, and fluorescence of the infected cells 
resulting from the expression of the  EGFP reporter 
gene (Fig. 8). As expected, Ad5/35F-EGFP easily pen-
etrated into RBM monocytes (32.66% of EGFP-positive 
cells), which confirms the data obtained earlier [16], 
and transduced granulocytes (42.86% of EGFP-positive 
cells) and blast cells (27.24% of EGFP-positive cells), 
which was first demonstrated. Meanwhile,  efficiency 
in penetration of the modified Ad5/35F-EGFP adeno-
virus in the subpopulation of T- and B-lymphocytes 
from human RBM was low (0.71% of EGFP-positive 
cells). The data on the efficient transduction of mono-
cyte, granulocyte, and blast cell populations with the 
modified Ad5/35F-EGFP adenovirus are consistent 
with  reports of a high level of CD46 expression in pop-
Ad5-EGFP   Ad5/35F-EGFP
Fig. 6. Penetration efficiency of the modified Ad5/35-
EGFP virus into leukocytes of human RBM 48 h after infec-
tion.
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k-   Ad5-IL2   Ad5/35F-IL2
Fig. 7. The level of interleukin-2 expression in leukocytes 
of human RBM transduced with recombinant adenovirus-
es, 48 h after infection.
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Fig. 8. Determination of leukocyte populations in the hu-
man RBM efficiently transduced by recombinant modified 
adenovirus Ad5/35F-EGFP. Adenovirus-infected cells 
(fluorescing) are shown in green. A – blast cells; B – gran-
ulocytes; C – monocytes; and D – lymphocytes.106 | ACTA NATURAE |  VOL. 3  № 3 (10)  2011
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ulations of these cells [17]. However, notwithstanding 
the data on the level of transcription of the CD46 gene 
in T- and B-lymphocytes which is comparable to that in   
cells of the myeloid differentiation branch [17, 18], the 
modified adenovirus did not efficiently penetrate into 
lymphocytes. This could be due to the specific regula-
tion of CD46 expression at the level of the protein.
CONCLUSIONS
A specific modification consisting in the substitution of 
the C-terminal knob domain of the Ad5 fiber for the 
analogous domain of the Ad35 fiber was used to obtain 
recombinant Ad5 containing the modified fiber and 
carrying the human IL2 gene. A manifold increase in   
efficiency in the penetration of this vector into  cells, 
as compared with the unmodified vector, was demon-
strated on KG-1A and U937 line cultures of human tu-
mor blood cells. A 30-fold increase in efficiency in the 
penetration of the modified vector in comparison with 
that for the unmodified vector was first demonstrat-
ed in  experiments on the transduction of the primary 
leukocyte culture from RBM taken from a healthy do-
nor, which ensures the expression of the human inter-
leukin-2 gene in them. Along with the efficient trans-
duction of RBM monocytes [16], the modified Ad5/35F 
was first shown to efficiently transduce granulocytes 
and blast cells of human RBM, while this vector does 
not penetrate into T- and B-lymphocyte subpopula-
tions.
Based on the results obtained in this study, it can be 
concluded that the modified Ad5/35F-IL2 adenovirus 
obtained can be used as a vector for  efficient delivery 
of the human interleukin-2 gene and for its application 
in the genetic therapy of different types of leukemia, as 
well as in the design of genetically engineered vaccines 
capable of efficiently delivering the antigen genes of 
different pathogens directly to the immunocompetent 
cells, including dendritic cells, which are professional 
antigen-presenting cells [19]. 
This study was supported by the Ministry of Education 
and Science of the Russian Federation (Government 
Contract № 02.512.11.2320).
REFERENCES
1. Tang D.C., Jennelle R.S., Shi Z., Garver R.I., Carbone D.P., 
Loya F., Chang C.H., Curiel D.T. // Hum. Gene Ther. 1997. 
V. 8. № 17. P. 2117–2124.
2. Tang D.C., Johnston S.A., Carbone D.P. // Cancer Gene 
Ther. 1994. V. 1. № 1. P. 15–20.
3. Gall J., Kass-Eisler A., Leinwand L., Falck-Pedersen E. // 
J. Virol. 1996. V. 70. № 4. P. 2116–2123.
4. Krasnykh V.N., Mikheeva G.V., Douglas J.T., Curiel D.T. // 
J. Virol. 1996. V. 70. P. 6839–6846.
5. Stevenson S.C., Rollence M., Marshall-Neff J., McClelland 
A. // J. Virol. 1997. V. 71. № 6. P. 4782–4790.
6. Shayakhmetov D.M., Papayannopoulou T., Stamatoyanno-
poulos G., Lieber A. // J. Virol. 2000. V. 74. P. 2567–2583. 
7. Zhang Y., Bergelson J.M. // J. Virol. 2005. V. 79. № 19. 
P. 12125–12131.
8. Melief C.J., Offringa R. // J. Immunol. 2001. V. 166. P. 5236–
5244. 
9. Shmarov M.M., Cherenova L.V., Shashkova E.V., Logunov 
D.Iu., Verkhovskaia L.V., Kapitonov A.V., Neugodova G.L., 
Doronin K.K., Naroditskiĭ B.S. // Mol. Gen. Mikrobiol. Viru-
sol. 2002. V. 2. P. 30–35.
10. Logunov D.Y., Zubkova O.V., Karyagina-Zhulina A.S., 
Shuvalova E.A., Karpov A.P., Shmarov M.M., Tutykhina 
I.L., Alyapkina Y.S., Grezina N.M., Zinovieva N.A., Ernst 
L.K., Gintsburg A.L., Naroditsky B.S. // J. Virol. 2007. V. 81. 
№ 18. P. 9641–9652.
11. Rogozhin V. N., Belousova R. V., Logunov D.Y., Shmarov 
M. M., Lunin V.G., Naroditsky B.S. // Vet. Meditsina. 2011. 
№ 2. P. 10-13 
12. Guardado-Calvo P., Llamas-Saiz A.L., Fox G.C., Langlois 
P., van Raaij M.J. // J. Gen. Virol. 2007. № 88. Pt 9. P. 2407–
2416.
13. Sakurai F., Mizuguchi H., Yamaguchi T., Hayakawa T. // 
Mol. Ther. 2003. V. 8. № 5. P. 813–821.
14. Gaggar A., Shayakhmetov D.M., Liszewski M.K., Atkin-
son J.P., Lieber A. // J. Virol. 2005. V. 79. № 12. P. 7503–7513.
15. Nilsson M., Ljungberg J., Richter J., Kiefer T., Magnusson 
M., Lieber A., Widegren B., Karlsson S., Fan X. // J. Gene 
Med. 2004. V. 6. № 6. P. 631–641.
16. Segerman A., Lindman K., Mei Y.F., Allard A., Wadell G. 
// Virology. 2006. V. 349. № 1. P. 96–111.
17. Christmas S.E., de la Mata Espinosa C.T., Halliday D., 
Buxton C.A., Cummerson J.A., Johnson P.M. // Immunol-
ogy. 2006. V. 119. № 4. P. 522–528.
18. Wang G., Liszewski M.K., Chan A.C., Atkinson J.P. // J. 
Immunol. 2000. V. 164. № 4. P. 1839–1846.
19. Wang H., Liu Y., Li Z., Tuve S., Stone D., Kalyushniy O., 
Shayakhmetov D., Verlinde C.L., Stehle T., McVey J., et al. 
// J. Virol. 2008. V. 82. № 21. P. 10567–10579.